Thoratecs LVAD shows Better Survival Results in a Year
Published By : 17 Apr 2015 |Published By : QYRESEARCH
At the yearly meeting of the International Society for Heart and Lung Transplantation, Thoratec presented its one year results from its real world study titled ROADMAP. The meeting was held in Nice in France on Friday. According to the results, patients who were given the Thoratec HeartMate II left ventricular assist device or LVAD presented an 80 per cent overall survival rate at the end of one year. This was in comparison to patients who received optimal medical management or OMM and presented an overall survival rate of 64 per cent at the end of a year.
Thoratec’s HeartMate II was also in alignment with the ROADMAP study’s key endpoint: a composite end point that measures survival as well as the functional movement of patients during a six minute walk being able to walk 75 meters longer than at baseline. An estimated 39 per cent patients in the HeartMate II group met this composite end point. This was significantly and statistically better than patients in the OMM group where only 21 per cent of the patients met with this criteria. The results of the study were summarized in a press release issued by the company.
The ROADMAP study is a non randomized postmark one which compares Thoratec’s HeartMate II therapy with the optimal medical management therapy in patients of heart failure. These patients have been classified as New York Heart Association or NYHA Class IIIB and IV. These patients also come under the categories 4 to 7 of the Interagency Registry for Mechanically Assisted Circulatory Support. The NYHA Class IV is a categorization of the most severe heart failure condition and patients suffer from severe symptoms even when they are resting. However, INTERMACS segments 4 through 7 are considered to be less severe than categories 1 through 3.